About Sialanar® and Prescribing Information
(320mcg/ml glycopyrronium equivalent to 400mcg/ml glycopyrronium bromide)
Sialanar® received a European Paediatric Use Marketing Authorisation (PUMA) on 15th September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
NICE published its latest evidence summary on “Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide” in February 2017
Summary of Product Characteristics (UK)
Healthcare Educational Materials (UK)
Reminder Information for Parent/Carer (UK)
Prescribing Information (Ireland)
Summary of Product Characteristics (Ireland)
NICE Evidence Summary
https://www.nice.org.uk/advice/es5/chapter/Key-points
Benefits of Sialanar®
The illustrations below do not represent the colour of Sialanar® or other glycopyrronium solutions
Product | Sialanar® |
---|---|
Mode of action | Antichollingeric |
Composition | 320mcg/ml glycopyrronium equivalent to 400mcg/ml glycopyrronium bromide |
Pack Sizes | 250ml or 60ml amber glass bottle (includes one 8 ml low density polyethylene oral syringe and one syringe adaptor) |
Appearance | Clear and colourless |
Flavour | Raspberry |
Viscosity | Aqueous solution |
Sweetener | Sucralose (E955) |
Lactose-free | Yes |
Carbohydrate free | Yes |
Gluten-free | Yes |
Storage conditions | Do not store above 25°C |
Suitable for feeding tubes | Yes – suitable for GJ, PEG and Nasogastric |
Sodium Free | Yes |
Sortbitol Free | Yes |
Fructose free | Yes |
Aspartame Free | Yes |
Tartrazine Free | Yes |
Shelf Life unopened | 2 years |
Shelf life once opened | 2 months |
Please refer to SMPC for dosing information.
UK-SIA-22-0132
Reviewed September 2022